ATE401057T1 - Verfahren zur einführung eines lipid-verknüpften teils in eine vorgeformte lipidanordnung mit mikrowellen - Google Patents

Verfahren zur einführung eines lipid-verknüpften teils in eine vorgeformte lipidanordnung mit mikrowellen

Info

Publication number
ATE401057T1
ATE401057T1 AT05807394T AT05807394T ATE401057T1 AT E401057 T1 ATE401057 T1 AT E401057T1 AT 05807394 T AT05807394 T AT 05807394T AT 05807394 T AT05807394 T AT 05807394T AT E401057 T1 ATE401057 T1 AT E401057T1
Authority
AT
Austria
Prior art keywords
lipid
linked moiety
microwaves
introducing
assembly
Prior art date
Application number
AT05807394T
Other languages
English (en)
Inventor
Yechezkel Barenholz
Olga Garbuzenko
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of ATE401057T1 publication Critical patent/ATE401057T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT05807394T 2004-10-08 2005-10-07 Verfahren zur einführung eines lipid-verknüpften teils in eine vorgeformte lipidanordnung mit mikrowellen ATE401057T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61750504P 2004-10-08 2004-10-08

Publications (1)

Publication Number Publication Date
ATE401057T1 true ATE401057T1 (de) 2008-08-15

Family

ID=35617473

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05807394T ATE401057T1 (de) 2004-10-08 2005-10-07 Verfahren zur einführung eines lipid-verknüpften teils in eine vorgeformte lipidanordnung mit mikrowellen

Country Status (8)

Country Link
US (1) US7985417B2 (de)
EP (1) EP1809246B1 (de)
JP (1) JP2008515929A (de)
AT (1) ATE401057T1 (de)
AU (1) AU2005295072A1 (de)
CA (1) CA2582242A1 (de)
DE (1) DE602005008270D1 (de)
WO (1) WO2006042270A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060015534A (ko) 2003-04-25 2006-02-17 더 펜 스테이트 리서치 파운데이션 성장 억제, 지질 유래된 생활성 화합물의 전신 전달을 위한방법 및 시스템
US9393315B2 (en) 2011-06-08 2016-07-19 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
EP2142167A2 (de) * 2007-03-30 2010-01-13 Epitarget As Akustisch sensitive wirkstofffreisetzungspartikel
MX2010003536A (es) 2007-10-02 2010-04-27 Kuhs Gmbh Composicion cosmetica o farmaceutica para aplicacion topica.
US9078812B2 (en) 2007-12-06 2015-07-14 The Bay Zoltan Foundation For Applied Research Particulate drug carriers as desensitizing agents
EP2451950B9 (de) * 2009-07-06 2016-11-23 Variation Biotechnologies Inc. Verfahren zur vesikelherstellung und darin hergestellte formulierungen
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
CN107261110A (zh) * 2010-06-19 2017-10-20 健康科学西部大学 Peg化脂质体包封的糖肽抗生素的新制剂
BR112013000394B8 (pt) 2010-07-06 2022-01-18 Variation Biotechnologies Inc Composição imunogênica, uso da mesma e método para preparar a referida composição
EP2663327A4 (de) 2011-01-13 2015-12-02 Variation Biotechnologies Inc Zusammensetzungen und verfahren zur behandlung von virusinfektionen
CN103796668B (zh) * 2011-09-28 2016-12-28 泰尔茂株式会社 含有血红蛋白的脂质体及其制造方法
US20140356399A1 (en) 2012-01-12 2014-12-04 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
EP4008354A1 (de) 2012-01-27 2022-06-08 Variation Biotechnologies Inc. Verfahren und zusammensetzungen für therapeutika
BR112015022819A8 (pt) * 2013-03-13 2019-11-26 Mallinckrodt Llc método para a preparação de um taxano lipossomal, composição compreendendo um lipossoma e taxano lipossomal
GB201612108D0 (en) 2016-07-12 2016-08-24 Univ Strathclyde Preperation of non-ionic surfactant vesicles and variants
FI3811931T3 (fi) 2018-06-20 2024-09-12 Fujifilm Corp Liposomikoostumukseen kapseloidun lääkkeen ja immuunitarkistuspisteinhibiittorin sisältävä yhdistelmälääkitys
WO2020071349A1 (ja) * 2018-10-01 2020-04-09 富士フイルム株式会社 薬物を内包するリポソーム組成物およびプラチナ製剤を含む組合せ医薬

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IS1685B (is) * 1990-12-11 1998-02-24 Bracco International B.V. Aðferð við að búa til fitukúlur (liposomes) sem eru gæddar auknum hæfileika til að draga í sig og halda í sér aðskotaefnum
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US6326353B1 (en) * 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
US6180134B1 (en) * 1993-03-23 2001-01-30 Sequus Pharmaceuticals, Inc. Enhanced ciruclation effector composition and method
SE9403245D0 (sv) * 1994-09-26 1994-09-26 Pharmacia Biosensor Ab Improvements relating to bilayer lipid membranes
US6214388B1 (en) * 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5616790A (en) * 1994-11-18 1997-04-01 California Institute Of Technology Lipid-based metal sensor
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
WO1998023948A1 (en) 1996-11-29 1998-06-04 The Board Of Trustees Of The Leland Stanford Junior University Arrays of independently-addressable supported fluid bilayer membranes and methods of use thereof
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
US7112337B2 (en) * 1999-04-23 2006-09-26 Alza Corporation Liposome composition for delivery of nucleic acid
CA2388173A1 (en) 1999-10-08 2001-04-19 Steven G. Boxer Lipid-bilayer arrays and methods of making and using same

Also Published As

Publication number Publication date
EP1809246B1 (de) 2008-07-16
CA2582242A1 (en) 2006-04-20
US20060121105A1 (en) 2006-06-08
JP2008515929A (ja) 2008-05-15
EP1809246A1 (de) 2007-07-25
AU2005295072A1 (en) 2006-04-20
US7985417B2 (en) 2011-07-26
DE602005008270D1 (de) 2008-08-28
WO2006042270A1 (en) 2006-04-20

Similar Documents

Publication Publication Date Title
ATE401057T1 (de) Verfahren zur einführung eines lipid-verknüpften teils in eine vorgeformte lipidanordnung mit mikrowellen
Cheng et al. Induction of bleb structures in lipid nanoparticle formulations of mRNA leads to improved transfection potency
DE69837274D1 (de) Verfahren zur verkapselung von nukleinsäuren in lipiddoppelschichten
BR0113477A (pt) Peptìdios de penetração em membranas e usos dos mesmos
PT1157041E (pt) Anticorpos para terapia e diagnostico de cancro
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
DE69616523D1 (de) Verfahren zur baladung von lipidvesikeln
CY1118629T1 (el) Εμβολιο ιου ερπητα ζωστηρα
AR037666A1 (es) Metodo para la identificacion de enzimas marcadores tumorales
EP1874793A4 (de) Abgabe von sirna durch neutrale lipid-zusammensetzungen
ATE200679T1 (de) Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
BRPI0414128A (pt) sistema e método para aumento de mamas
BRPI0915142A8 (pt) Polipeptídeos, ácido nucleico e usos dos mesmos
ATE316333T1 (de) Verfahren zur in-vivo abgabe therapeutischer agenzien mittels liposomen
BR112013004865A2 (pt) lípidos adequados para entrega lipossomal de codificadores de proteínas rna
BRPI0713421A2 (pt) Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero
BRPI0415308A (pt) incorporação especìfica de local de aminoácidos redox ativos em proteìnas
BRPI0511235A (pt) preparado tópico e método para a administração transdérmica e localização de agentes terapêuticos
DK1633784T3 (da) OVR110 antistofsammensætninger og -anvendelsesfremgangsmåder
Yotsu-Yamashita et al. Localization of pufferfish saxitoxin and tetrodotoxin binding protein (PSTBP) in the tissues of the pufferfish, Takifugu pardalis, analyzed by immunohistochemical staining
Brogden et al. Isolation and analysis of membrane lipids and lipid rafts in common carp (Cyprinus carpio L.)
WO2005112546A3 (en) Mucinous glycoprotein (muc-1) vaccine
AU4850601A (en) Protein stabilised emulsions
ATE514718T1 (de) Peptabody für krebsbehandlung
Raja et al. Effects of sodium chloride on membrane fusion and on the formation of aggregates of potassium channel KcsA in Escherichia coli membrane

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties